Most life sciences CEOs expect to grow their head counts over the next 3 years: KPMG survey

On a routine basis in recent years, headlines about layoffs in the biopharma industry have surfaced as companies large and small have been cutting costs and restructuring. Over the last 10 days, for example, Fierce has written about dismissals at Bristol Myers Squibb, Novartis, Lexicon Pharmaceuticals, Johnson & Johnson, Gilead Sciences, Merck, Sonata Therapeutics, Medigene and Alector Therapeutics.

But those days may soon be over, according to leaders in the life sciences sector, who participated in an annual survey conducted by KPMG.